Method development and validation for the identification and quantitation of gamma-hydroxybutyrate in urine, blood, and oral fluid using gas chromatography-mass spectrometry by Carr, Amanda
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
Method development and
validation for the identification and
quantitation of
gamma-hydroxybutyrate in urine,
blood, and oral fluid using gas
chromatography-mass
spectrometry
https://hdl.handle.net/2144/31166
Boston University
 BOSTON UNIVERSITY 
SCHOOL OF MEDICINE 
 
Thesis 
 
METHOD DEVELOPMENT AND VALIDATION FOR THE IDENTIFICATION 
AND QUANTITATION OF GAMMA-HYDROXYBUTYRATE IN URINE, 
BLOOD, AND ORAL FLUID USING GAS CHROMATOGRAPHY-MASS 
SPECTROMETRY  
 
by 
 
AMANDA LEE CARR  
B.S., State University of New York at Geneseo, 2016 
 
 
 
Submitted in partial fulfillment of the 
requirements for the degree of 
Master of Science 
2018 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2018 by 
AMANDA LEE CARR 
All rights reserved 
 
 
 Approved by 
 
 
 
First Reader  
 Sabra Botch-Jones, M.S., M.S., M.A., D-ABFT-FT 
Assistant Professor, Program in Biomedical Forensic Sciences  
 Department of Anatomy & Neurobiology 
  
  
Second Reader  
 Dr. Gail Cooper, B.Sc.,(Hons), M.Sc., Ph.D., CChem FRSC FHEA 
Director of Forensic Toxicology 
New York City Office of Chief Medical Examiner 
 
  
  
  
 
 
iv 
 
ACKNOWLEDGMENTS 
First, I would like to thank my parents for their unwavering love and support 
throughout my educational journey.  Without them, none of this would have been 
possible.  I would also like to thank Sabra Botch-Jones for all of her help and guidance 
over the past two years.  I have learned so much, and you have helped me recognize my 
passion for toxicology.  Additionally, I would like to thank all of those at the Forensic 
Toxicology Laboratory of the New York City Office of the Chief Medical Examiner that 
helped me enhance my knowledge of forensic toxicology.  Specifically, I would like to 
express my gratitude to Dr. Gail Cooper and Michelle Dumit, who have taken time out of 
their busy schedules to provide me with assistance and review my work.  Finally, I would 
like to thank all of my friends and colleagues at the Boston University School of 
Medicine for their patience, support, and encouragement during this process. 
 
 
v 
 
METHOD DEVELOPMENT AND VALIDATION FOR THE IDENTIFICATION 
AND QUANTITATION OF GAMMA-HYDROXYBUTYRATE IN URINE, 
BLOOD, AND ORAL FLUID USING GAS CHROMATOGRAPHY-MASS 
SPECTROMETRY 
 
 
AMANDA LEE CARR 
 
ABSTRACT 
Gamma-hydroxybutyrate (GHB) is an endogenous compound in the human body, 
found in regions of the mammalian brain and believed to be a cerebral 
neurotransmitter.1,2 GHB also acts as a powerful central nervous system depressant 
commonly used as a “date rape” drug due to its hypnotic and sedative properties.1  The 
drug has also been used medicinally to treat alcohol withdrawal, opiate-withdrawal 
syndrome, and narcolepsy.3–5  
Toxicological analysis of GHB in drug facilitated sexual assault (DFSA) cases is 
typically performed using blood and urine specimens.1  However, due to the endogenous 
nature of GHB, toxicological interpretation of these biological specimens can be complex 
and challenging.1,4  Additionally, urine and blood analysis of GHB can be impacted by 
sample collection, sample analysis times, and sample storage conditions.6,7  Due to the 
challenges and limitations associated with blood and urine analysis of GHB along with 
the prominence of GHB in DFSA cases, it would be beneficial to determine the 
possibility of GHB analysis using alternative biological matrices. 
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 The primary goal of this research was to develop a sample preparation method 
that could accurately and reliably identify and quantify GHB in oral fluid, as an 
alternative biological matrix.  Additionally, this research was carried out to compare the 
identification and quantitation capabilities of GHB in oral fluid to that of traditional 
biological matrices, specifically urine and blood.  The methods employed in this study 
utilized gas chromatography – mass spectrometry (GC-MS) instrumentation in order to 
correctly identify GHB.  A deuterated internal standard, GHB-d6, was used to quantify all 
samples.  The methods were assessed using the parameters set forth by the Scientific 
Working Group of Forensic Toxicologists (SWGTOX) for quantitative analysis methods.  
The following factors were considered: calibration model, bias, precision, limit of 
detection and quantitation, carryover, and interferences. 
 Urine and blood samples were prepared using 200 uL of urine (UTAK 
Laboratories, Inc., Valencia, CA, U.S.A.) or blood (Equitech-Bio Inc., Kerrville, TX, 
U.S.A.), varying amounts of the 200 mg/L working calibrator and control solution 
prepared using certified reference standards (Cerilliant, Round Rock, TX, U.S.A.), and 50 
uL of 100 mg/L working internal standard solution resulting in an internal standard 
concentration of 25 mg/L in each sample.  Solid phase extraction (SPE) was performed 
using United Chemical Technologies (UCT), Inc. (Bristol, PA, U.S.A) Clean Screen 
GHB columns (ZSGHB020) on all samples.1  Samples were reconstituted, derivatized, 
and analyzed using GC-MS.  
  Oral fluid samples were prepared using 1.0 uL of drug-free oral fluid, and 1.0 
mg/mL (as salt) in methanol GHB received from Cerilliant.  The samples were spiked 
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with 1 uL of 1.0 mg/mL (as salt) in methanol GHB-d6 received from Cerilliant.  Each 
sample had an internal standard concentration of 10 mg/L.  Samples were fortified with 
100 uL of ethyl acetate, and derivatized with 100 uL of bis(trimethyl)trifluoroacetamide 
(BSTFA) with 1% Trimethylchlorosilane (TMCS) received from Cerilliant.  The samples 
were incubated, and analyzed using GC-MS.8 
 All analyses were conducted using an Agilent 7890A GC system, Agilent 5975C 
Mass Detector System (MSD), and an Agilent 7683B Autosampler (Agilent 
Technologies Inc. Santa Clara, CA).  The chromatographic component was carried out 
using an Agilent HP5-MS 30m x 250um x 0.25um capillary column and an Agilent HP-
5MS 15m x 250um x 0.25um capillary column.  All data was analyzed using Agilent 
MSD ChemStation software (version E.02.02.1431).  The method has a total length of 
12.75 minutes.  Selective ion monitoring (SIM) was used to monitor the ions of interest 
for each analyte.  GHB-d6 was monitored using the ions 239, 240, and 241.  GHB was 
monitored using the ions 233, 234, 235.1 
 Results revealed that GHB and GHB-d6 could be identified and differentiated due 
to their fragmentation patterns.  All calibration curves for the three matrices exhibited R2 
values > 0.98 using a linear dynamic range of 5-100 mg/L with a minimum of four 
calibration points.  The limit of detection for the three matrices was determined to be 1 
mg/L, and the limit of quantitation for the three matrices was determined to be 5 mg/L.  
Bias and precision were analyzed at concentrations of 8 mg/L, 45 mg/L, and 90 mg/L for 
each matrix.  All urine and blood samples were calculated to be within the acceptance 
range of +20% bias and +20% coefficient of variation.  Oral fluid samples were outside 
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of the +20% acceptance range for both bias and coefficient of variation.  The highest 
concentration analyzed that did not produce carryover into subsequent matrix blanks was 
found to be 350 mg/L for each matrix.  Significant interferences were found to be present 
in urine and blood samples, but negligible for all oral fluid samples.  
 This research illustrates that the developed sample preparation method can be 
used to accurately and reliably identify GHB in oral fluid.  Additionally, this research 
suggests that the quantitation capabilities of GHB in oral fluid are not as accurate and 
precise as those of urine and blood.  Therefore, the developed method has better 
qualitative analysis capabilities, while the urine and blood methods have better 
quantitative analysis capabilities for forensic toxicology casework.    
  
 
 
 
ix 
 
TABLE OF CONTENTS 
 Page 
Title Page i 
Reader’s Approval Page iii 
Acknowledgments iv 
Abstract v 
Table of Contents ix 
List of Tables  xii 
List of Figures  xiii 
List of Abbreviations xiv 
1. Introduction 1 
1.1 Chemistry and Background 1 
1.2 GHB Use 2 
1.2.1 History and Legal Use 
1.2.2 Illegal Use                                                                                                                
1.2.3 GHB as a “Date Rape” Drug 
1.2.4 Dose Effects 
      1.3 Pharmacology of GHB  
            1.3.1 Pharmacodynamics 
            1.3.2 Pharmacokinetics 
      1.4 Detection Methods and Analytical Interpretation 
2 
3
4 
4 
5 
5 
6 
8 
x 
 
      1.5 Research Objectives 10 
2. Materials and Methods 
2.1 Theory of Instrumentation  
2.2.1 Gas Chromatography  
2.2.2 Mass Spectrometry 
       2.2 Materials 
2.2.1 Standards/Reagents 
2.2.2 GC-MS Instrumentation  
      2.3 Methods 
            2.3.1 GC-MS Instrument Parameters 
            2.3.2 Sample Preparation 
                  2.3.2.1 Urine and Blood 
                  2.3.2.2 Oral Fluid 
            2.3.3 Method Validation 
                  2.3.3.1 Calibration Model 
                  2.3.3.2 Bias and Precision 
                  2.3.3.3 Limit of Detection and Limit of Quantitation 
                  2.3.3.4 Carryover 
                 2.3.3.5 Interferences Studies 
 
3. Results and Discussion 
        3.1 Detection of Analyte 
 
11 
11 
11 
12 
13 
13 
14 
14 
14 
16 
16 
17 
19 
19 
19 
20 
21 
21 
23 
23 
 
xi 
 
        3.2 Method Validation 
            3.2.1 Calibration Model 
            3.2.2 Bias and Precision 
            3.2.3 Limit of Detection and Limit of Quantitation 
            3.2.4 Carryover 
            3.2.5 Interference Studies  
4. Conclusions 
       4.1 Summary of Findings 
       4.2 Significance of Findings  
 
5. Future Research 
       5.1 Additional Validation Parameters 
       5.2 Additional Matrices 
 
Appendix A: Limit of Detection Chromatographic Data  
Appendix B: Limit of Quantitation Chromatographic Data 
Appendix C: Carryover Study Chromatographic Data 
Appendix D: Interferences Study Chromatographic Data 
 
Bibliography   
Curriculum Vitae  
 
25 
25 
29 
31 
31 
32 
35 
35 
35 
36 
36 
37 
38 
40 
42 
44 
47 
49 
xii 
 
LIST OF TABLES 
 Page 
Table 1.  Lot Numbers of Certified Reference Materials. 
Table 2.  GC Oven Parameters 
14 
15 
Table 3.  GC-MS Ramp Cycle Parameters. 15 
Table 4.  Preparation of Urine and Blood Calibration Curve Samples. 16 
Table 5.  Preparation of Oral Fluid Calibration Curve Samples. 18 
Table 6.  R2 Values for Five Calibration Curves Run in Urine. 26 
Table 7.  R2 Values for Five Calibration Curves Run in Blood. 26 
Table 8.  R2 Values for Five Calibration Curves Run in Oral Fluid. 27 
Table 9.  Bias and Precision Results for GHB in Urine. 30 
Table 10.  Bias and Precision Results for GHB in Blood. 30 
Table 11.  Bias and Precision Results for GHB in Oral Fluid. 
Table 12.  Concentrations of Endogenous GHB-d6 and GHB in Urine. 
Table 13.  Concentrations of Endogenous GHB-d6 and GHB in Blood. 
31 
33 
34 
  
 
xiii 
 
LIST OF FIGURES 
 Page 
Figure 1.  Chemical Structure of Gamma-hydroxybutyrate. 1 
Figure 2.  GBL and GHB Equilibrium Under Aqueous Conditions. 2 
Figure 3.  GHB Synthesis and Metabolism. 8 
Figure 4.  Chromatogram of 25 mg/L Urine Calibration Sample Run on 30 m  
                Column. 
23 
Figure 5.  Chromatogram of 25 mg/L Urine Calibration Sample Run on 15 m  
                Column. 
24 
Figure 6.  Mass Spectrum of GHB-d6 with Major Ions 239, 240, 241. 24 
Figure 7.  Mass Spectrum of GHB with Major Ions 233, 234, 235. 25 
Figure 8.  Calibration Curves of Five Separate Runs of GHB in Urine. 27 
Figure 9.  Calibration Curves of Five Separate Runs of GHB in Blood. 28 
Figure 10.  Calibration Curves of Five Separate Runs of GHB in Oral Fluid. 29 
  
 
xiv 
 
LIST OF ABBREVIATIONS 
ASB 
amu 
BSTFA 
CA 
CH3OH   
Academy Standards Board 
Atomic mass units 
Bis(trimethyl)trifluoroacetamide 
California 
Methanol 
CNS 
DFSA 
DI  
EM                        
Central nervous system 
Drug facilitated sexual assault 
Deionized  
Electron multiplier 
FDA 
g 
Food and Drug Administration 
Gram 
GABA Gamma-aminobutyric acid  
GBL 
GC 
GC-MS 
Gammabutyrolactone 
Gas chromatography 
Gas chromatography-mass spectrometry 
GHB  
kg 
LC/MS/MS 
LOD 
LOQ 
Gamma-hydroxybutyrate  
Kilogram 
Liquid chromatography tandem mass spectrometry 
Limit of detection 
Limit of quantitation 
xv 
 
m 
mm 
mM 
MA 
mg 
min 
Meter 
Millimeter 
Millimolar 
Massachusetts  
Milligram 
Minute 
MS 
MSD 
m/z 
NH4OH 
PA 
QC 
R2 
rpm 
SIM 
SPE 
SWGTOX 
TMCS 
TX 
uL 
um 
Mass spectrometry 
Mass detector system 
Mass-to-charge ratio 
Ammonium hydroxide 
Pennsylvania 
Quality control 
Correlation coefficient  
Rotations per minute 
Selective ion monitoring 
Solid phase extraction 
Scientific Working Group for Forensic Toxicologists 
Trimethylchlorosilane 
Texas 
Microliter 
Micrometer 
xvi 
 
U.S.A. 
WA 
°C 
 
β 
 
%CV 
% 
United States of America 
Washington 
Degrees Celsius 
Beta 
Percent of the coefficient of variation 
Percent 
 
 
 
  
  
 
 
1 
 
1. INTRODUCTION 
1.1 Chemistry and Background 
Gamma-hydroxybutyrate (GHB) is an endogenous metabolite of the inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA), and acts on the central nervous 
system (CNS) as a depressant.1,2  The compound is found in regions of the mammalian 
brain and believed to be a cerebral neurotransmitter.1,3  The naturally occurring form of 
GHB has also been found in various other body tissues.  In vivo synthesis of GHB results 
from metabolic breakdown of GABA to succinic semialdehyde and further reduction to 
GHB.5 
  Structurally, the compound is a hydroxylated, short-chain fatty acid (Figure 1).9  
It contains four carbon atoms, eight hydrogen atoms, 
and three oxygen atoms, resulting in a molecular 
weight of 126.1 atomic mass units (amu).  Generally, 
the compound is found in its water-soluble sodium salt 
form as a white or off-white powder, or as a clear, 
odorless liquid.4,10 
  Analysis of GHB can be challenging due to its acidity, high polarity, and high 
solubility when dissolved in an aqueous solution.  Additionally, when GHB is dissolved 
in water, it exists in equilibrium with gammabutyrolactone (GBL), a precursor of GHB 
(Figure 2).  GBL is formed when the GHB molecule condenses, forming a cyclic ester 
with a five-membered ring.9  GHB predominates when the pH of the matrix is greater 
Figure 1. Chemical Structure of 
Gamma-hydroxybutyrate. 
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than 4.72, and GBL predominates when the pH is below 4.72.  In plasma, GBL 
predominates because GHB is converted to GBL by the enzyme lactonase.4 
 
Figure 2. GBL and GHB Equilibrium Under Aqueous Conditions.9 
 
1.2 GHB Use 
1.2.1 History and Legal Use 
GHB was first synthesized in Europe in the 1960s as an anesthetic drug, during 
Henry Laborit’s search for an “active, synthetic analogue of GABA that readily crossed 
the blood-brain barrier and persisted longer than GABA”.2,3  The drug was introduced as 
an intravenous general anesthetic agent lacking analgesic properties.  Use of the drug as a 
surgical anesthetic on humans was first reported in 1962 by Blumenfled et al.2  However, 
within a short period of time use of GHB as an anesthetic stopped due to reported side 
effects of grand mal seizures and coma.4 The drug has also been used medicinally to treat 
alcohol withdrawal, opiate-withdrawal syndrome, and narcolepsy.3,4 Xyrem (sodium 
oxybate), a drug developed by Orphan Medical Inc., is currently used to treat patients 
suffering from narcolepsy/cataplexy.1,5   
In July 2002, the sodium salt of GHB, sold as Xyrem, for the treatment of 
cataplexy was approved by the United States Food and Drug Administration (FDA).11  
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The prescription form of GHB provided to these patients is categorized as a Schedule III 
substance under the Controlled Substances Act.  However, illegal trafficking of the 
prescription form of GHB is associated with Schedule I penalties of the Controlled 
Substances Act.4,5  The Xyrem Success Program was established to promote safe use of 
the drug.  The program includes “a centralized distribution and dispensing system with 
tracking of prescription shipments, a physician and patient registry, and compulsory 
educational materials for patients and physicians along with an initial post-marketing 
surveillance program.”  The FDA extended the therapeutic use of sodium oxybate in 
2005 to allow for the treatment of narcolepsy patients with excessive daytime sleepiness.2 
 
1.2.2 Illegal Use 
 In the United States during the 1990s it was discovered that GHB usage resulted 
in euphoric and sedative effects, along with the release of short-term human growth 
hormones.2  This resulted in the use and abuse of GHB as both a club drug and a steroid 
alternative used by body builders.3  Additionally, GHB was sold in health stores for 
weight control purposes.1  However, due to reports of toxic effects, the FDA issued a 
recall of supplements containing GHB and GBL in 1999.2 
Low doses of GHB are commonly used as a club drug due to the stimulant and 
euphoric effects that result.5  Other desirable effects include relaxation, loss of 
inhibitions, increased sociability, and increased sexual awareness.2  As a club drug, GHB 
is commonly referred to as “liquid ecstasy” or “scoop.”10  At higher concentrations, GHB 
is a hypnotic with strong sedative powers, leading to its use as a “date rape” drug.4  
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Generally, the drug is abused orally by dissolving the white powder in water or other 
liquids.1  The colorless, odorless, highly water soluble properties of the liquid also allows 
for GHB to be easily dissolved in other beverages.2,10   
 In July 1998, the increased misuse and abuse of GHB led to a Congressional 
Hearing and the classification of GHB as a Schedule I substance under the Controlled 
Substances Act.5 
 
1.2.3 GHB as a “Date Rape” Drug 
 Higher doses of GHB are frequently used in drug-facilitated sexual assaults 
(DFSA) cases.  High concentrations of GHB can cause powerful sedative properties such 
as loss of inhibitions, deep sleep, or coma.4  Unlike other drugs used in DFSA, GHB can 
cause a victim to move from an alert state to an unconscious state within 10 to 15 minutes 
after ingestion.5  GHB is frequently used in DFSA because the substance is easy to 
produce, or it can be readily purchased online or on the street.  Use of GHB in DFSA is 
popular because of the ease at which it can be unknowingly added to a beverage.4  In 
DFSA cases, GHB is commonly administered with alcohol.  The interaction of GHB and 
alcohol can produce “synergistic CNS depressant effects” resulting in anterograde 
amnesia.5  
 
1.2.4  Dose Effects 
 For treatment of narcolepsy, prescribed doses of sodium oxybate range from 4.5 
to 9.0 g at bedtime.  The typical street dose of GHB is 2-6 g (25-75 mg/kg).  However, 
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this amount can greatly vary based on a user’s experience.  Experienced GHB users can 
ingest up to 30 g.2  At low doses GHB has stimulant and euphoric effects.  Higher doses 
of GHB produce hypnotic and sedative properties, and are usually seen in DFSA cases.  
It has been documented that doses of 10 mg/kg cause amnesia; 20-30 mg/kg cause sleep; 
and doses of 50 mg/kg or higher produce anesthesia.12   
 Withdrawal symptoms may result in chronic users that consume high doses of 
GHB.  Doses of 40 g per day have been associated with withdrawal symptoms, including 
anxiety, tremors, hallucinations, paranoia, nystagmus, impaired memory, hypertension, 
and tachycardia.13  However, it is difficult to determine the exact dose affiliated with 
withdrawal symptoms because GHB is often obtained as a powder over the internet, and 
many of the individuals that use GHB are polydrug abusers.2   
 
1.3 Pharmacology of GHB 
1.3.1 Pharmacodynamics 
 Pharmacodynamics is the study of how a drug affects the human body, including 
receptor binding, post-receptor effects, and chemical interaction.4  GHB is endogenous in 
the human body, and acts as both a precursor and metabolic product of the 
neurotransmitter GABA.  GHB binding sites are located throughout the mammalian 
brain, and it is hypothesized that the physiologic and pharmacologic effects of exogenous 
GHB “result from modulation of GABAB receptors directly as a partial agonist and 
indirectly through GHB-derived GABA”.2  However, the exact mechanism is unknown.2 
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 GHB is a CNS depressant.  The administration of exogenous GHB results in 
behavioral changes such as euphoria and sedation due to selective agonist activity at the 
GABAB receptors.2  Additional experimental in vitro and in vivo animal studies have 
illustrated that exogenous GHB has an effect on a number of neurotransmitter systems 
including dopamine release and synthesis, serotonin turnover, increased dynorphin and 
encephalin concentrations, noradrenergic transmission, and inhibition of glutamate 
release.14   
       
1.3.2 Pharmacokinetics 
 Pharmacokinetics is the study of how a drug is absorbed, distributed, metabolized, 
and excreted by the human body.4  The absorption of GHB is rapid and capacity-limited.2  
Research suggests that absorption may be enhanced when the drug is consumed on an 
empty stomach.4  Studies using healthy volunteers have indicated that peak GHB plasma 
concentrations occur within 20-45 minutes after ingestion of 25-50 mg GHB/kg.  Clinical 
research has indicated that effects occur within 15-20 minutes after oral administration, 
and peak effects occur within 30-60 minutes.  Additionally, GHB undergoes extensive 
first-pass metabolism following oral consumption.4  
GHB is a poorly protein bound drug with a relatively small distribution volume 
(0.4-0.6 L/kg).15  However, GHB is lipid-soluble, allowing it to cross the blood-brain 
barrier where it exerts its primary effect.4     
As GHB moves throughout the human body it is metabolized primarily through 
the conversion to succinic semialdehyde.  Following this conversion, it is then 
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transformed into succinate, followed by conversion to carbon dioxide and water via the 
Krebs cycle.  There are several minor metabolic pathways that can also transform GHB.  
This includes the reduction of GHB to succinic semialdehyde by the enzyme GHB-
oxoacidtranshydrogenase, and the β-oxidation of GHB illustrated in Figure 3.2  
Elimination of GHB occurs as a result of biotrasformation rather than from renal 
excretion.2  The kidneys are responsible for the excretion of <1-2% of a therapeutic dose 
of GHB (25 mg/kg twice daily for 7 days).  GHB elimination occurs rapidly in a non-
linear fashion with a plasma elimination half-life of approximately 20-30 minutes for 
typical therapeutic doses.15  Case reports have indicated that the elimination of non-
therapeutic, larger doses of GHB occurs via zero-order kinetics.16    
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Figure 3.  GHB Synthesis and Metabolism.  Major metabolic pathways are illustrated 
with solid arrows, and minor pathways are shown with dashed arrows.14 
 
1.4 Detection Methods and Analytical Interpretation 
 There are different analytical approaches that can be used to identify and 
quantitate GHB in biological specimens.  Many methods analyze GHB by converting to 
GBL.1  This conversion is achieved by using a concentrated dehydrating acid, such as 
sulfuric acid, followed by extraction into an organic solvent.4  This sample can then be 
injected into a gas chromatograph-mass spectrometer (GC-MS).  Other methods require 
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derivatization of GHB by silation followed by GC-MS analysis.  Unlike the previously 
described method, derivatization of GHB by silation does not account for GBL within the 
sample.1,4  Liquid chromatography-tandem mass spectrometry (LC- MS/MS) can also be 
utilized to analyze GHB within biological samples.   
 GHB is typically identified and quantified using blood and urine specimens.  
However, due to the endogenous nature of GHB, toxicological interpretation of these 
biological specimens can be challenging.  Most scientists have agreed that GHB 
concentrations exceeding 10 mg/L illustrate the presence of exogenous GHB.1,4  
However, interpretation of GHB concentrations in urine can become more complicated if 
sample analysis is delayed a few months due to the possibility of in vitro GHB 
formation.6  Additionally, storage temperature can effect endogenous GHB levels in 
urine, with increases of up to 404% at room temperature, 140-208% in refrigerated 
samples, and 88-116% in frozen specimens over a 6-month period.17  Finally, the 
maximum detection time of GHB after ingestion is 12 hours in urine, illustrating the 
importance of collecting samples quickly and efficiently.4,18 Similarly, GHB analysis in 
blood can be challenging.  It has been reported that citrate buffer, used in blood collection 
tubes, can result in falsely elevated GHB levels.19  Furthermore, the maximum detection 
time of GHB after ingestion is 6 hours in blood, again illustrating the necessity of quick 
and efficient sample collection.4,16 Postmortem analysis of GHB also poses a challenge to 
toxicologists.  It has been determined that GHB concentrations can artificially increase in 
postmortem blood samples within a short period of time if not properly stored and 
preserved.7  A study of 387 postmortem cases unrelated to GHB use submitted for 
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toxicological analysis between the years 2010 and 2012 revealed that GHB was detected 
at levels between 10-50 mg/L in 73% of cases, and between 51-193 mg/L in 9% of 
cases.20 
 
1.5 Research Objectives 
 Due to the use and abuse of GHB, specifically in DFSA cases, there is a need for 
a reliable, confirmatory method for the detection and quantitation of GHB in biological 
samples submitted for forensic toxicological analysis.  Additionally, because of the 
limitations and challenges associated with blood and urine analysis of GHB, it would be 
beneficial to determine the possibility of GHB analysis using alternative biological 
matrices. 
 The primary goal of this research was to develop methods that could accurately 
and reliably identify and quantify GHB in an alternative biological matrix, specifically 
oral fluid.  Additionally, this research was carried out to compare the identification and 
quantitation capabilities of GHB in oral fluid to that of traditional biological matrices, 
specifically blood and urine.  The methods employed in this study utilized GC-MS 
instrumentation in order to correctly identify GHB.  GHB-d6, a deuterated internal 
standard, was used to quantify all samples.  The developed methods were assessed using 
the parameters set forth by the Scientific Working Group of Forensic Toxicologists 
(SWGTOX) for quantitative analysis methods.21  The following factors were considered: 
calibration model, bias, precision, limit of detection and quantitation, carryover, and 
interferences. 
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2. MATERIALS AND METHODS 
2.1 Theory of Instrumentation 
2.1.1 Gas Chromatography 
 Gas chromatography (GC) is a separatory technique used in chemistry.  The GC 
resolves the various components of a mixture based on differing molecular properties.  
Initially, the liquid sample is automatically injected, using an autosampler, into a heated 
port of the instrument, causing it to evaporate.  The vapor is then transported through the 
instrument’s column which is housed in the column oven, by an inert carrier gas, also 
known as a mobile phase.  The column is housed in the oven in order to keep it at a hot 
enough temperature to ensure that the analytes elute in a reasonable amount of time.  The 
column, also referred to as the instrument’s stationary phase, is composed of a viscous 
liquid bound to the inside of a capillary tube.  The type of column used for analysis is 
selected based on the chemistry of the analytes that are to be separated.  Most GC 
analyses require long, narrow open tubular columns composed of fused silica and coated 
with polyimide.22  Ultimately, separation occurs as a result of the partitioning of sample 
components between the stationary phase and the mobile phase according to the 
molecule’s distribution constant.23  The sample components pass through the column at 
different rates and elute at unique times.  
 As the analytes are separated and elute from the column, they move through a 
detector.  The detector produces a response that is displayed on a computer as a 
chromatogram.  A chromatogram is a graph that plots the detector response as a function 
of elution time for each component of the sample.  A compound’s retention time, the time 
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that passes between injection of the mixture onto the column and arrival at the detector, is 
recorded on the chromatogram.22  
 
2.1.2 Mass Spectrometry  
 Mass spectrometry (MS) is an analytical technique used for the analysis of the 
masses of atoms, molecules, or fragments of molecules.22  Ultimately, all molecules 
fragment in distinctive patterns, allowing mass spectrometry to elucidate a molecule’s 
structural composition.23  
To obtain the mass spectrum, a plot of detector response versus mass-to-charge 
ratio (m/z), the species of interest must first be converted into the gaseous state.  The 
gaseous species is then ionized by the instrument’s ion source.22  While different methods 
of ionization exist, electron ionization is a method commonly employed.  During electron 
ionization, the gaseous sample interacts with high-energy electrons emitted from a heated 
filament.  After emission from the filament, the electrons are focused and accelerated in a 
narrow beam.  This beam of ionizing electrons collides with the gaseous sample, 
transferring kinetic energy, and overcoming the molecule’s first ionization potential to 
form a positively charged ion.  After this initial ionization, excess energy results in the 
production of fragment ions unique to the sample molecule.23    
  Following ionization, the sample is accelerated towards the mass analyzer by an 
electric field.  At the mass analyzer, the chemical species are separated according to their 
m/z.  Quadrupole mass analyzers are frequently employed that consist of four parallel 
rods surrounding a central axis.  The four rods have an applied radiofrequency and direct 
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current.  The ions are sent through the quadrupole, and only those ions with a particular 
m/z can migrate through and reach the instrument’s detector depending on the applied 
voltages.22   As the separated ions reach the detector the intensity of each m/z is recorded, 
resulting in a unique mass spectrum.23        
 
2.2 Materials 
2.2.1 Standards/Reagents 
Deuterated GHB (GHB-d6) with a concentration of 1.0 mg/mL was used as an 
internal standard, and purchased from Cerilliant (Round Rock, TX, U.S.A.).  BSTFA 
with 1% TMCS (N,O,- bis(trimethyl)trifluoroacetamide with 1% Trimethylchlorosilane) 
purchased from Cerilliant was used as a derivatizing agent.  Additional reagents included 
methanol, acetone, ethyl acetate, and ammonium hydroxide purchased from Fisher 
Scientific (Waltham, MA, U.S.A).  100 mM phosphate buffer (pH 6.0) was prepared in 
the laboratory.  A pH meter, Oakton pH 700 meter from Fisher Scientific, was used to 
verify the pH of the buffer.  Additionally, the eluting solvent, 99% methanol and 1% 
ammonium hydroxide (CH3OH/NH4OH (99/1)), was prepared in the laboratory.  
Negative blood purchased from Equitech-Bio Inc. (Kerrville, TX, U.S.A.) and negative 
urine purchased from UTAK Laboratories Inc. (Valencia, CA, U.S.A.) were also used.  
Deionized water (DI) was also required for this analysis.  Further sample preparation was 
performed using a solid phase extraction manifold from Waters, Inc. (Milford, MA, 
U.S.A.).  Clean Screen GHB 200mg/10 mL solid phase extraction columns from UCT, 
Inc. (Bristol, PA, U.S.A) were used. 
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Table 1: Lot Numbers of Certified Reference Materials.  All certified reference 
materials were stored in a freezer at -20°C. 
 
Product Company Lot Number 
GHB Sodium Salt Cerilliant FE05121507 
GHB-D6 Sodium Salt Cerilliant FE06241602 
BSTFA (with 1% TMCS) Cerilliant FN08181601 
 
 
2.2.2 GC-MS Instrumentation  
 All analyses were conducted using an Agilent 7890A Gas Chromatogram (GC) 
system, Agilent 5975C Mass Detector System (MSD), and an Agilent 7683B 
Autosampler (Agilent Technologies Inc., Santa Clara, CA, U.S.A.).  The 
chromatographic component was carried out using an Agilent HP5-MS 30m x 250um x 
0.25um capillary column and an Agilent HP-5MS 15m x 250um x 0.25um capillary 
column.  All data was analyzed using Agilent MSD ChemStation software (version 
E.02.02.1431).  Additional statistical analyses were performed using Microsoft Excel 
(Microsoft Corporation, Redmond, WA, U.S.A.).    
 
2.3 Methods 
2.3.1 GC-MS Instrument Parameters 
 The instrument’s initial oven temperature was held at 70°C for 1 minute, with 
additional oven parameters shown in Table 1.  Ramp 1 of the oven occurred at a rate of 
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15°C/min to reach a final temperature of 100°C, followed by Ramp 2 at a rate of 
20°C/min to reach a final temperature of 175°C.  Ramp 3 occurred at a rate of 35°C/min 
to reach a final temperature of 280°C, and was held for 3 min (Table 2).  Total run time 
for the method was 12.75 min.  The front inlet using split mode with a split ratio of 2.6:1 
had an initial temperature of 250°C and a split flow of 3.12 mL/min.  Helium was used as 
the mobile phase.  The mass detector had an electron multiplier (EM) voltage of 890, 
gain factor of 1, and 4 min solvent delay.  Data was collected in selected ion monitoring 
(SIM) mode.  The ions monitored for the internal standard, GHB-d6, were m/z 239, 240, 
and 241.  The ions monitored for GHB were m/z 233, 234, and 235.1   
 
Table 2: GC Oven Parameters. 
Initial 
Temperature (°C) 
Initial Time (min) Maximum 
temperature (°C) 
Equilibration Time 
(min) 
70 1.00 450 0.50 
 
 
Table 3: GC-MS Ramp Cycle Parameters. 
Ramp Number Rate (°C/min) Final 
temperature 
(°C) 
Hold time 
(min) 
Run time 
(min) 
Initial --- 70 1 1 
Ramp 1 15 100 0 3 
Ramp 2 20 175 0 6.75 
Ramp 3 35 280 3 12.75 
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2.3.2 Sample Preparation 
2.3.2.1 Urine and Blood 
 Using 1.0 mg/L (as salt) in methanol GHB-d6 received from Cerilliant, 100 mg/L 
GHB-d6 working internal standard was prepared.  Using two ampules of 1.0 mg/L (as 
salt) in methanol GHB received from Cerilliant, 200 mg/L GHB working calibrator and 
control solution was prepared.  Calibrators, quality control (QC) samples, and 
“unknowns” were prepared using 200 uL of urine or blood, varying amounts of the 200 
mg/L working calibrator and control solution, and 50 uL of 100 mg/L working internal 
standard solution resulting in an internal standard concentration of 25 mg/L in each 
sample (Table 4).  Samples were prepared in 16 x 125 mm glass test tubes. 
 
Table 4: Preparation of Urine and Blood Calibration Curve Samples. The table 
shows the quantities of each component used to prepare the calibration curve.   
 
Calibrator (mg/L) / 
Sample  
Matrix (uL) 100 mg/L GHB-d6 
Working Internal 
Standard Solution 
(uL) 
200 mg/L GHB 
Working 
Calibrator and 
Control Solution 
(uL) 
5 200 50 5 
10 200 50 10 
25 200 50 25 
50 200 50 50 
100 200 50 100 
Negative control 200 50 0 
 
  
Preparing samples for analysis was a two-step process. First, 1 mL of acetone was 
added to each sample.  Samples were vortexed for approximately 15 seconds, and then 
centrifuged at 3000 revolutions per minute (rpm) for 10 min.  The acetone layer (top 
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layer) was transferred to a glass test tube and evaporated at 80°C using a Multivap 
Nitrogen Evaporator (Organomation, Berlin, MA, U.S.A.). The dried sample extracts 
were reconstituted using 200 uL 100 mM phosophate buffer (pH 6.0).  The samples were 
vortexed for approximately 15 seconds. 
 Next, solid phase extraction (SPE) was performed using United Chemical 
Technologies (UCT), Inc. Clean Screen GHB columns (ZSGHB020) on all samples to 
remove unwanted matrix components.  Before the sample was applied, the columns were 
first conditioned by applying 3 mL methanol, 3 mL DI water, and 3 mL 100 mM 
phosphate buffer (pH 6.0), respectively.  Each was allowed to flow through the column 
by gravity.  The sample was then applied, and allowed to flow through by gravity.  The 
samples were dried for 15 min under high vacuum before the drug was eluted using 1.0 
mL CH3OH/NH4OH (99/1).  After collecting the extract, the eluate was evaporated to 
dryness at 40°C using nitrogen.  Derivatization was performed by adding 100 uL ethyl 
acetate and 100 uL BSTFA with 1% TMCS to each sample.  The samples were vortexed, 
and incubated using an Organomation heating block for 30 min at 70°C.1  After 
incubation, the samples were removed from the heating block and allowed to cool before 
being transferred to GC vials with inserts.  All samples were run using the previously 
described GC-MS method.  
2.3.2.2 Oral Fluid 
The following procedure was developed based on work previously published by 
De Paoli and Bell.8 Calibrators, QC samples, and “unknowns” were prepared using 1.0 
uL of drug-free oral fluid, and 1.0 mg/mL (as salt) in methanol GHB received from 
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Cerilliant.  To each sample, 1 uL of 1.0 mg/mL (as salt) in methanol GHB-d6 received 
from Cerilliant was added for an internal standard concentration of 10 mg/L.  Unlike the 
procedure developed by De Paoli and Bell, samples were first fortified with 100 uL of 
ethyl acetate.  Samples were then derivatized with 100 uL of BSTFA (with 1% TMCS) 
received from Cerilliant.8  This modification to the procedure produced the best 
quantitative results.  All samples were prepared in 4 mL glass vials with caps.  
Calibrators contained varying amounts of GHB ranging from 1 uL to 20 uL (Table 5). 
 
 
Table 5: Preparation of Oral Fluid Calibration Curve Samples. The table shows the 
quantities of each component used to prepare the calibration curve.  GHB and GHB-d6 
received from Cerilliant were 1.0 mg/mL (as salt) in methanol. 
 
Calibrator 
(mg/L)/Sample 
Oral 
fluid 
(uL) 
GHB-d6 
(uL) 
GHB 
(uL) 
Ethyl 
acetate 
(uL) 
BSTFA 
with 1% 
TMCS 
(uL) 
5 1 1 1 100 100 
10 1 1 2 100 100 
25 1 1 5 100 100 
50 1 1 10 100 100 
100 1 1 20 100 100 
Negative control 1 1 0 100 100 
 
Samples were vortexed for approximately 5 seconds after all components were 
added to glass vials.  The samples were then incubated in an oven (Thermo Fisher 
Scientific, Marietta, OH, U.S.A.) for 30 min at 70°C.8  After incubation, the samples 
were removed from the oven and allowed to cool before being transferred to GC vials 
with inserts.  All samples were run using the previously described GC-MS method.  
 
19 
 
2.3.3 Method Validation 
 Validation studies for quantitative analyses were performed using SWGTOX 
guidelines.  Data analysis was performed using Agilent MSD ChemStation.  GHB-d6 was 
used to quantify GHB.  The following validation parameters were considered: calibration 
model, bias, precision, limit of detection and quantitation, carryover, and interferences.21  
2.3.3.1 Calibration Model 
 The calibration model was studied by preparing five point calibration curves.  
Negative matrix samples were spiked at concentrations of 5, 10, 25, 50, and 100 mg/L.  
This range of concentrations was used because of the endogenous nature of GHB.  Due to 
the endogenous nature of GHB, a concentration cutoff of 10 mg/L is commonly used to 
confirm the presence of exogenous GHB.  The calibration curve was prepared by plotting 
the response ratio against the concentration ratio.  The calibration curve was re-prepared 
and run on the GC-MS five times in blood, urine, and oral fluid.  Each calibration curve 
was prepared and studied using Agilent MSD ChemStation.  
2.3.3.2 Bias and Precision 
 Bias and precision studies were performed to determine the accuracy and 
reproducibility of identifying and quantifying GHB in each matrix.  Triplicates of 
“unknown” samples with concentrations of 8 mg/L, 45 mg/L, and 90 mg/L were 
evaluated.  Along with the “unknown” samples, a calibration curve was prepared for each 
matrix ranging from 5 mg/L to 100 mg/L.  A negative control was also evaluated.  All 
samples were analyzed by GC-MS, and quantitated using Agilent MSD ChemStation.  
The calculated concentrations generated using Agilent MSD ChemStation were then used 
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to calculate the mean and standard deviation for each concentration in Microsoft Excel.  
Additionally, the percent of the coefficient of variation (%CV) was calculated for each of 
the three concentrations along with the percent deviation from the mean, and the percent 
bias.  The calculations are given below: 
 
%CV = standard deviation / mean response 
 
% deviation from mean = (avg. concentration deviation / avg. concentration) x 100 
 
Bias (%) = (mean concentration – nominal concentration) / (nominal concentration) x 
100 
 
 
2.3.3.3 Limit of Detection and Limit of Quantitation 
 Using the established calibration model, the limit of detection (LOD) and limit of 
quantitation (LOQ) were determined for GHB in each matrix.  The LOD is an estimate of 
the lowest concentration of analyte that can be detected and differentiated from a blank 
matrix.  The LOQ is an estimate of the lowest concentration of an analyte that can be 
reliably measured.22  The LOD and LOQ of the method were determined by preparing 
calibration curve samples, controls, and “unknowns.”  The “unknowns” were spiked at 
concentrations of 1, 2, 3, and 4 mg/L and run in triplicate.  Due to the endogenous nature 
of GHB, it was not necessary to prepare samples at concentrations lower than 1 mg/L.    
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Using the calibration model, the concentrations of each sample were calculated.  In this 
study, the limit of quantitation was defined as the lowest concentration of GHB that could 
be calculated within +20% accuracy using %CV.  
2.3.3.4 Carryover 
 Analyte carryover into subsequent samples was assessed.  Analyte carryover can 
result in inaccurate qualitative and quantitative data.  To determine the analyte carryover, 
calibration curve samples, controls, “unknowns” spiked at high concentrations were 
prepared in each matrix.  Carryover samples were prepared at concentrations ranging 
from 100 mg/L to 350 mg/L, and matrix blanks containing the internal standard were also 
prepared.  High concentration samples were followed by the analysis of a blank matrix 
sample.  To determine the presence of carryover, all sample were quantitated using 
Agilent MSD ChemStation. 
2.3.3.5 Interference Studies 
 Potential matrix interferences were evaluated for blood, urine, and oral fluid.  
Additionally, the potential interference of the internal standard, GHB-d6, was studied, 
along with that of endogenous GHB.  The presence of matrix interferences and 
endogenous GHB was evaluated using ten different sources of antemortem urine, drug-
free postmortem blood from the Federal Aviation Administration collected in 2014, and 
oral fluid from living subjects.  The samples were prepared and subject to the same 
conditions as the “unknowns” previously described.  They were then analyzed using GC-
MS and the concentration of GHB was quantitated using Agilent MSD ChemStation. 
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 To determine the effects of the internal standard on each matrix, samples were 
prepared without spiking the internal standard or GHB.  All samples were then subject to 
the same conditions as the “unknowns” previously described.  They were then analyzed 
using GC-MS and the concentration of GHB was quantitated using Agilent MSD 
ChemStation.  
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3. RESULTS AND DISCUSSION 
3.1 Detection of Analyte 
 The method has a total run time of 12.75 minutes.  SIM was used to monitor the 
ions of interest for each analyte.  GHB-d6 was monitored using the ions 239, 240, and 
241.  GHB was monitored using the ions 233, 234, 235.  Both analytes were able to be 
identified and differentiated due to their fragmentation patterns. 
Five separate runs were carried out per matrix to determine the average retention 
times of the two analytes.  GHB and GHB-d6 co-elute.  Using the 30 m column, GHB-d6 
elutes with an average retention time of 5.975 minutes with a standard deviation of 0.018 
minutes, and GHB elutes with an average retention time of 6.000 minutes with a standard 
deviation of 0.017 minutes.  Using the 15 m column, GHB-d6 elutes with an average 
retention time of 4.275 with a standard deviation of 0.011, and GHB elutes with an 
average retention time of 4.296 with a standard deviation of 0.013.   
 
Figure 4: Chromatogram of 25 mg/L Urine Calibration Sample Run on 30 m 
Column.  GHB-d6 elutes at 5.99 minutes, and GHB elutes at 6.018 minutes.  
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Figure 5: Chromatogram of 25 mg/L Urine Calibration Sample Run on 15 m 
Column.  GHB-d6 elutes at 4.243 minutes, and GHB elutes at 4.263 minutes. 
 
 
 
Figure 6: Mass Spectrum of GHB-d6 with Major Ions 239, 240, and 241. 
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Figure 7: Mass Spectrum of GHB with Major Ions 233, 234, and 235. 
 
3.2 Method Validation 
3.2.1 Calibration Model 
 The calibration model is a necessary component of analytical method validation 
because it describes the correlation between signal response and analyte concentration in 
a sample.  The linear dynamic range of the calibration curve should be prepared to 
encompass the range of values that is expected to be detected in casework.1   
Calibration curves with a working range of 5 mg/L to 100 mg/L were run a total 
of five times for each matrix.  GHB was quantified using GHB-d6.  All calibration curves 
were prepared by plotting the response ratio by the concentration ratio, and the fit was 
determined to be quadratic.  Additionally, the correlation coefficient (R2) was calculated 
for each run.  All R2 values were calculated using a minimum of four calibration points.  
Using urine, the average R2 value over all runs was calculated to be 0.997 (Table 
6), and using blood the average R2 value over all runs was calculated to be 0.992 (Table 
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7).  For oral fluid, the average R2 value over all runs was calculated to be 0.995 (Table 8).  
The R2 value for all calibration curves in all three matrices was above the minimum 
accepted value of 0.98 using a minimum of four calibration points.21 
 
Table 6: R2 Values for Five Calibration Curves Run in Urine. 
Run # Calibration points R2 
1 5 1 
2 5 0.994 
3 5 0.998 
4 5 0.997 
5 5 0.995 
 
Table 7: R2 Values for Five Calibration Curves Run in Blood. 
Run # Calibration points R2 
1 5 0.989 
2 4 0.992 
3 4 0.992 
4 4 0.997 
5 4 0.992 
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Table 8: R2 Values for Five Calibration Curves Run in Oral Fluid. 
Run # Calibration points R2 
1 5 0.999 
2 5 1 
3 4 0.986 
4 4 0.999 
5 5 0.999 
 
 
Figure 8: Calibration Curves of Five Separate Runs of GHB in Urine.  The average 
R2 value of the five runs was calculated to be 0.997. The R2 value of each curve with a 
minimum of four points was above the minimum accepted value of 0.98. 
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Figure 9: Calibration Curves of Five Separate Runs of GHB in Blood.  The average 
R2 value of the five runs was calculated to be 0.992. The R2 value of each curve with a 
minimum of four points was above the minimum accepted value of 0.98. 
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Figure 10: Calibration curves of five separate runs of GHB in oral fluid.  The 
average R2 value of the five runs was calculated to be 0.9948. The R2 value of each curve 
with a minimum of four points was above the minimum accepted value of 0.98. 
 
3.2.2 Bias and Precision 
 Bias is a measure of how close calculated concentrations are to the actual, target 
concentrations.  Precision is a measure of variation in samples that are known to contain 
the same concentration.24  Concentrations of 8 mg/L, 45 mg/L, and 90 mg/L were 
evaluated in all matrices.  Each concentration sample was prepared in triplicate, and the 
data was used to calculate bias and precision as percentages.  SWGTOX guidelines state 
that bias and precision values should not exceed 20% at each concentration.21   
The evaluation of bias and precision in urine and blood revealed a % bias and 
%CV lower than 20% for all concentrations (Table 9 and Table 10).  This illustrates that 
the methods are accurate and precise when quantifying the concentration of the analyte in 
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both urine and blood.  The highest % bias was observed at the 8 mg/L concentration for 
both urine and blood, illustrating greater instances of inaccuracy at lower concentrations.  
The evaluation of bias and precision in oral fluid revealed a % bias and %CV greater than 
20% (Table 11).  Specifically, higher instances of bias and precision were observed at the 
8 mg/L concentration and 45 mg/L concentration, illustrating a greater amount of 
inaccuracy associated with this matrix and sample preparation method. 
 
Table 9: Bias and Precision Results for GHB in Urine. 
Target 
concentration 
(mg/L) 
Average 
calculated 
concentration 
(mg/L) 
Calculated 
concentration 
standard 
deviation 
(mg/L) 
%CV % 
deviation 
from mean 
% Bias 
8 9.2300 0.0356 0.3856 0.3611 15.3750 
45 41.6633 1.9509 4.6825 4.3150 -7.4148 
90 90.8067 4.9718 5.4751 5.0755 0.8963 
 
Table 10: Bias and Precision Results for GHB in Blood. 
Target 
concentration 
(mg/L) 
Average 
calculated 
concentration 
(mg/L) 
Calculated 
concentration 
standard 
deviation 
(mg/L) 
%CV % 
deviation 
from mean 
% Bias 
8 9.3633 0.1731 1.8485 1.6139 17.0417 
45 37.6133 0.9878 2.6262 0.3611 -16.4150 
90 89.5900 4.2032 4.6916 4.2788 -0.4556 
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Table 11: Bias and Precision Results for GHB in Oral Fluid. 
Target 
concentration 
(mg/L) 
Average 
calculated 
concentration 
(mg/L) 
Calculated 
concentration 
standard 
deviation 
(mg/L) 
%CV % 
deviation 
from mean 
% Bias 
8 5.8100 1.1754 20.2314 18.9329 -27.3750 
45 57.3167 0.7829 1.3659 1.2872 27.3704 
90 89.7967 10.7341 11.9538 10.9333 -0.2259 
 
3.2.3 LOD and LOQ 
 For this study, the limit of detection was determined to be the lowest 
concentration to generate a significant instrument response.  However, this concentration 
could not be quantified within +20% accuracy using the calibration model.   The limit of 
quantitation was determined to be the lowest concentration that could be quantified 
within +20% accuracy using the calibration model.  The limit of detection in all matrices 
was determined to be 1 mg/L, and the limit of quantitation was determined to be 5 mg/L 
(See Appendix A and Appendix B). 
3.2.4 Carryover 
 Blanks were run after samples spiked with high concentrations, ranging from 100-
350 mg/L of GHB, to determine the presence of analyte carryover from subsequent 
samples.  Using urine and blood, GHB carryover was determined to be below the limit of 
quantitation, and therefore negligible.  For oral fluid, it was determined that when using 
this method, GHB carryover from previous samples was negligible, and could not be 
quantitated (See Appendix C). 
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 Due to the endogenous nature of GHB, a concentration cutoff of 10 mg/L is 
commonly used to confirm the presence of exogenous GHB.1  Therefore, the negligible 
amounts seen in these matrices were not considered to be significant. 
3.2.5 Interference Studies 
 Ten specimens were analyzed for urine, blood, and oral fluid.  For each matrix, 
ten samples were run without the addition of GHB or GHB-d6, and another set of ten was 
run with the addition of the internal standard, GHB-d6, only.  The signal of the analyte 
was measured to determine the influence of the matrix, as well as endogenous GHB and 
GHB-d6 concentrations. 
Quantitation revealed that of the ten urine samples run without the addition of 
GHB and GHB-d6, concentrations of endogenous GHB ranged from less than 1 mg/L to 
6.10 mg/L.  Of the ten urine samples run with the addition of GHB-d6 only, 
concentrations of endogenous GHB ranged from less than 1 mg/L to 13.15 mg/L (See 
Table 12).  
Analysis of ten postmortem drug-free blood samples from 2014 stored in 
collection tubes containing potassium oxalate (20.00 mg) and sodium fluoride (100.00 
mg), illustrated elevated levels of endogenous GHB.  Quantitation of samples without the 
addition of GHB and GHB-d6, revealed concentrations of endogenous GHB detected at 
levels of 0 mg/L to 310.93 mg/L.  Quantitation of the ten blood samples with the addition 
of GHB-d6 only, revealed concentrations of endogenous GHB from 0 mg/L to 27.85 
mg/L (See Table 13). 
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Quantitation of ten antemortem oral fluid samples revealed the presence of no 
interferences.  Endogenous GHB concentrations in all samples were calculated to be 0 
mg/L (See Appendix D). 
 
Table 12. Concentrations of Endogenous GHB-d6 and GHB in Urine. 
Urine Sample Concentration without 
addition of GHB-d6 and 
GHB (mg/L) 
Concentration without 
addition of GHB (mg/L) 
1 0 0.03 
2 0 0.02 
3 6.1 13.15 
4 5.85 9.72 
5 0 0.98 
6 0 1.48 
7 0 0.84 
8 0 1.51 
9 0 0.31 
10 0 3.13 
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Table 13. Concentrations of Endogenous GHB-d6 and GHB in Blood. 
Blood Sample Concentration without 
addition of GHB-d6 and 
GHB (mg/L) 
Concentration without 
addition of GHB (mg/L) 
1 27.14 11.33 
2 0 15.98 
3 0 18.85 
4 10.20 9.00 
5 27.85 167.14 
6 16.42 71.61 
7 0 0.22 
8 0 0.46 
9 0 0.40 
10 0 0.38 
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4. CONCLUSIONS 
4.1 Summary of Findings  
The results of this study demonstrate that GHB and GHB-d6 could be identified 
and differentiated in all matrices due to their fragmentation patterns using the GC-MS 
method with a total run time of 12.75 minutes.  All calibration curves for the three 
matrices exhibited R2 values > 0.98 using a linear dynamic range of 5-100 mg/L, using a 
minimum of four calibration points as per SWGTOX guidelines.19  The limit of detection 
for the three matrices was determined to be 1 mg/L, and the limit of quantitation for the 
three matrices was determined to be 5 mg/L.  Bias and precision were analyzed at 
concentrations of 8 mg/L, 45 mg/L, and 90 mg/L for each matrix.  All urine and blood 
samples were calculated to be within the acceptance range of +20% bias and +20% 
coefficient of variation.  Oral fluid samples were outside of the +20% acceptance range 
for both bias and coefficient of variation.  The highest concentration that did not produce 
carryover into subsequent matrix blanks was found to be 350 mg/L for each matrix.  
Interferences were found to be significant (>10 mg/L) for one of the ten urine samples, 
and for all ten of the postmortem blood samples.  However, interferences were found to 
be negligible for all oral fluid samples.  
 
4.2 Significance of Findings 
Currently, GHB is prominently seen in DFSA cases.  Toxicological analysis of 
GHB in DFSA cases is typically performed using blood and urine specimens.  However, 
there are challenges and limitations associated with blood and urine analysis.  The 
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primary goal of this research was to develop a sample preparation method that could 
accurately and reliably identify and quantify GHB in oral fluid, an alternative biological 
matrix.  Additionally, this research was carried out to compare the identification and 
quantitation capabilities of GHB in oral fluid to that of traditional biological matrices, 
specifically urine and blood. 
This research illustrates that the developed sample preparation method can be 
used to accurately and reliably identify GHB in oral fluid.  Furthermore, this research 
suggests that the quantitation capabilities of GHB in oral fluid are not as accurate and 
precise as those of urine and blood.  Therefore, the developed method has better 
qualitative analysis capabilities, while the methods utilizing urine and blood have better 
quantitative analysis capabilities for forensic toxicology casework.  Finally, this research 
demonstrated that oral fluid contains fewer interferences when compared to urine and 
blood analysis of exogenous GHB.   
 
5. Future Research 
5.1 Additional Validation Parameters 
 Additional SWGTOX validation parameters should be explored and compared for 
all three matrices.  It would be beneficial to determine the stability of GHB in oral fluid 
as compared to urine and blood under different storage conditions.  GHB should be 
prepared in all of the matrices and stored in various temperature conditions for differing 
lengths of time.  This will allow for the determination of how quickly GHB degrades in 
each condition, and the effect that degradation has on identification and quantitation.  
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Furthermore, this study will help determine the difference in interferences among the 
three matrices when subjected to the same conditions.   Additionally, it would be 
beneficial to determine the effect of freeze-thaw cycles on the specimens being evaluated.  
Finally, it would be beneficial to perform further interference studies using commonly 
encountered drugs such as marijuana, cocaine, and heroin.    
 In addition, as the forensic toxicology community adopts the Academy Standards 
Board’s (ASB) Standard Practices for Method Validation in Forensic Toxicology, further 
validation parameters should be considered.  The ASB Standard states that dilution 
integrity should be assessed for quantitative methods.  Dilution integrity should be 
assessed due to the possibility of samples containing low specimen volume.  
Additionally, dilution integrity is necessary in the analysis of samples that contain 
excessively high concentrations that fall outside of the calibration range.  These samples 
must be diluted, and brought to an analyte concentration within the validated calibration 
range.25 
5.2 Additional Matrices 
 This study can be expanded to include additional nontraditional matrices such as 
hair, vitreous humor, and plasma.  These additional matrices should be studied to 
determine if they can also be used to accurately and reliably identify and quantitate GHB.  
Furthermore, the results from these additional nontraditional matrices should be 
compared to those of urine, blood, and oral fluid to compare quantitative and qualitative 
analytical capabilities. 
38 
 
APPENDIX A:  LIMIT OF DETECTION CHROMATOGRAPHIC DATA 
 
Figure A: 1 mg/L Sample of GHB in Urine Run on 15 m Column.  GHB peak at 
4.274 minutes, and GHB-d6 peak at 4.253 minutes. 
 
 
Figure B: 1 mg/L Sample of GHB in Blood Run on 15 m Column. GHB peak at 4.284 
minutes, and GHB-d6 peak at 4.263 minutes. 
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Figure C: 1 mg/L Sample of GHB in Oral Fluid Run on 30 m Column.  GHB peak at 
6.014 minutes, and GHB-d6 peak at 5.990 minutes. 
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APPENDIX B:  LIMIT OF QUANTITATION CHROMATOGRAPHIC DATA. 
 
Figure A: 5 mg/L Sample of GHB in Urine Run on 15 m Column.  GHB peak at 
4.305 minutes, and GHB-d6 peak at 4.284 minutes. 
 
 
 
 
 
Figure B: 5 mg/L Sample of GHB in Blood Run on 15 m Column.  GHB peak at 
4.284 minutes, and GHB-d6 peak at 4.263 minutes. 
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Figure C: 5 mg/L Sample of GHB in Oral Fluid Run on 30 m Column.  GHB peak at 
6.043 minutes, and GHB-d6 peak at 6.022 minutes. 
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APPENDIX C:  CARRYOVER STUDY CHROMATOGRAPHIC DATA 
 
Figure A: Solvent Blank Following 350 mg/L Sample of GHB in Urine Run on 15 m 
Column.  GHB-d6 peak at 4.284 minutes. 
 
 
 
 
Figure B: Solvent Blank Following 350 mg/L Sample of GHB in Blood Run on 15 m 
Column.  GHB-d6 peak at 4.284 minutes. 
 
43 
 
 
 
Figure C: Solvent Blank Following 350 mg/L Sample of GHB in Oral Fluid Run on 
30 m Column.  GHB-d6 peak at 5.980 minutes. 
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APPENDIX D:  INTERFERENCES STUDY CHORMATOGRAPHIC DATA 
 
Figure A: Urine Sample Analyzed Without the Addition of GHB-d6 or GHB.  GHB-
d6 peak present at 4.284 minutes, and GHB peak present at 4.295 minutes. 
 
 
Figure B: Urine Sample Analyzed With the Addition of GHB-d6 only.  GHB-d6 peak 
present at 4.274 minutes, and GHB peak present at 4.295 minutes. 
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Figure C: Blood Sample Analyzed Without the Addition of GHB-d6 or GHB.  GHB-
d6 peak present at 4.659 minutes, and GHB peak present at 4.295 minutes. 
 
 
Figure D: Blood Sample Analyzed With the Addition of GHB-d6 only.  GHB-d6 peak 
present at 4.295 minutes, and GHB peak present at 4.315 minutes. 
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Figure E: Oral Fluid Sample Run Without the Addition of GHB-d6 or GHB.  GHB-
d6 peak present at 5.959 minutes. 
 
 
Figure F: Oral Fluid Sample Run With the Addition of GHB-d6 only.  GHB-d6 peak 
present at 5.959 minutes. 
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